FOI release

Freedom of Information responses from the MHRA - week commencing 4 July 2022

The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 4 July 2022

• From: Medicines and Healthcare products Regulatory Agency
• Published: 21 December 2023

Documents

Freedom of Information request on professional misconduct within the MHRA workplace (FOI 22/722)

HTML

Freedom of Information request on the adverse reactions reported following the COVID-19 vaccinations (FOI/735)

HTML

Freedom of Information request on adverse reaction reports received from Basildon University Hospital, Southend Hospital and Broomfield Hospital (FOI 22/743)

HTML

Freedom of Information request on information regarding Panadol Extra Soluble Tablets (FOI 22/747)

HTML

Freedom of Information request on the details and information for product Silvercloud (FOI 22/764)

HTML

Freedom of Information request on the summary of risk management plan for Formoterol Fumarate/Fluticasone Propionate (FOI 22/725)

HTML

Freedom of Information request on the data showing the risk of the combined contraceptive pill in the over 50's (FOI 22/727)

HTML

Freedom of Information request on the adverse reactions reported regarding beclomethasone, betamethasone, clobetasol, hydrocortisone and mometasone (FOI 22/752)

HTML

Freedom of Information request on the yellow card scheme and the COVID-19 vaccinations (FOI 22/772)

HTML

Freedom of Information request on the vaccine for Brain Tumours from Northwest Biotherapeutics (FOI 22/780)

HTML

Freedom of Information request on the RMP for Xaqua 5mg tablets (FOI 22/751)

HTML

FOI-22-751-1

PDF, 773 KB, 21 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on the batch numbers that appear most often in the adverse reactions reported following an AstraZeneca COVID-19 vaccine (FOI 22/762)

HTML

FOI-22-762-1

PDF, 405 KB, 1 page

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on the clinical trial data for the AstraZeneca COVID-19 vaccine (FOI 22/715)

HTML

Freedom of Information request on the summaries of Yellow Card reporting (FOI 22/745)

HTML

FOI-22-745-1

PDF, 420 KB, 34 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

FOI-22-745-2

PDF, 538 KB, 34 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Freedom of Information request on the details of framework agreements that contract were awarded for (FOI 22/760)

HTML

Freedom of Information request on the clinical study reports for Keytruda (FOI 22/773)

HTML

Freedom of Information request on the UK Public Assessment Report for Benzylpenicillin Sodium 600 mg powder for solution for injection / infusion (FOI 22/792)

HTML

Freedom of Information request on the clinical overview for Nuromol Dual Action Pain Relief 200mg/500mg tablets (FOI 22/812)

HTML

FOI-22-812-1

PDF, 12.8 MB, 77 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Medicines and Healthcare products Regulatory Agency (MHRA) responses to freedom of information (FOI) requests for week commencing 4 July 2022

Published 21 December 2023